All In Biotech

Drug Trial Radar · NCT07780643

A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-1)

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of GSK5784283 (Felcorekibart) as an Add-On Therapy in Adults and Adolescents With Uncontrolled Asthma (PERSIST ASTHMA-1)

Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 514 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

514

Planned (sponsor's estimate)

Start

Aug 27, 2026

Primary completion

Feb 15, 2029

Study completion Oct 11, 2029

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Aug 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study aims to demonstrate the superiority of GSK5784283 compared to placebo in reducing the annualized rate of clinically meaningful asthma exacerbations.

Conditions

  • Asthma

Interventions

  • GSK5784283Drug

    GSK5784283 will be administered.

  • PlaceboDrug

    Placebo will be administered.

  • Standard of careDrug

    Standard of care will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized rate of clinically significant asthma exacerbationsTime frame: Up to Week 52

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Miami Lakes, Florida · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.